Medpace (NASDAQ:MEDP), a clinical contract research organization, reported strong Q2 2025 earnings, achieving GAAP revenue of $603.3 million and EPS of $3.10, surpassing estimates of $538.8 million and $2.98, respectively. The positive results led management to raise forecasts for the remainder of FY2025, reflecting ongoing operational success and top-line growth.
Want More Context? 🔎
Snowflake Stock Is on Fire. But Can the Momentum Last?
Snowflake (NYSE: SNOW), an AI and data platform specialist, has witnessed its stock rise nearly 40% year to date, significantly outperforming the S&P 500's 7% increase, driven by its focus on AI and rapid revenue growth. However, concerns arise as the company continues to report substantial quarterly losses despite a market capitalization of approximately $72 billion. Want More Context? 🔎
Read more